Phio Pharmaceuticals financials
$1.03+1.98%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$4.3M | -$4.2M | -$2.5M | -$2.5M | -$2.3M | -$1.9M | -$1.7M | -$1.6M | -$1.9M | -$2.2M | -$1.9M | -$2.8M |
| Net income | -$4.1M | -$4.0M | -$2.4M | -$2.4M | -$2.2M | -$1.8M | -$1.6M | -$1.5M | -$1.8M | -$2.2M | -$1.9M | -$2.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.36 | $-0.34 | $-0.25 | $-0.44 | $-0.45 | $-0.41 | — | $-1.54 | $-3.62 | $-0.47 | $-2.53 | $-10.25 |
| EBITDA | -$4.3M | -$4.2M | -$2.5M | -$2.5M | -$2.3M | -$1.9M | -$1.7M | -$1.6M | -$1.9M | -$2.2M | -$1.8M | -$2.8M |
| Operating cash flow | -$4.0M | -$4.0M | -$2.1M | -$2.1M | -$2.5M | -$1.3M | -$1.4M | -$2.0M | -$1.8M | -$2.0M | -$2.4M | -$2.9M |
| Free cash flow | -$4.0M | -$4.0M | -$2.1M | -$2.1M | -$2.5M | -$1.3M | -$1.4M | -$2.0M | -$1.8M | -$2.0M | -$2.4M | -$2.9M |
| Diluted shares | 11.6M | 11.6M | 9.4M | 5.5M | 4.8M | 4.3M | — | 1.0M | 0.5M | 4.6M | 0.7M | 0.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $13.0M | $17.0M | $21.0M | $10.7M | $10.8M | $13.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $14.3M | $17.4M | $21.5M | $11.5M | $11.3M | $13.4M |
| Total liabilities | $1.7M | $950.0K | $1.3M | $1.7M | $1.2M | $1.3M |
| Shareholders' equity | $12.6M | $16.5M | $20.1M | $9.8M | $10.1M | $12.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology